Azathioprine

Imuran 50mg

TAH Drug Code	OIMU
Indications	As an adjunct for the prevention of rejection in renal homotransplantation. Treatment of SLE, severe RA, acute & chronic leukemia.
Dosing	Adult Transplantation initial dose 5 mg/kg/day, maintenance dose 1-4 mg/kg/day. Other conditions 1-3 mg/kg/day.
Hepatic Impairment	Dose adjustment not necessary
Renal Impairment	Dose adjustment required
Contraindications	Hypersensitivity to 6-mercaptopurine. Pregnancy or patients who are likely to become pregnant in the near future.
Adverse Effects	Common: Nausea and vomiting (12%) Serious: Pericarditis, Skin cancer, Pancreatitis, Hypersensitivity, Acute myeloid leukemia, Hematologic toxicity, Leukopenia (Renal transplant, more than 50%; rheumatoid arthritis, 28%), Leukopenia (Severe), <2500 cells/mm[3] (renal transplant, 16%; rheumatoid arthritis, 5.3%), Macrocytic anemia, Myelodysplastic syndrome, Myelosuppression (5%), Pancytopenia, Thrombocytopenia, Hepatotoxicity (<1%), Lymphoma involves liver, Veno-occlusive disease of the liver, Hypersensitivity reaction, Malignant lymphoma (0.5%), T-cell lymphoma, Hepatosplenic, Progressive multifocal leukoencephalopathy, Adenocarcinoma of lung, Infectious disease (renal transplant, 20%; rheumatoid arthritis, <1%), Neoplastic disease (0.5-11.9%)
Pregnancy	Human Data Suggest Risk in 3rd Trimester
Lactation	No (Limited) Human Data - Probably Compatible
More Info	UpToDate